Washington, DC 20006-5349
HELPLINE
Data from a positive phase 2/3 clinical trial evaluating the effectiveness of a drug for mesothelioma was just published in the Journal of the American…
Today, the Mesothelioma Applied Research Foundation (Foundation) announced its 2023 award recipients. The awards will be presented during the organization’s International Symposium on Malignant Mesothelioma…
The Mesothelioma Applied Research Foundation announced the recipients of its most recent research grants cycle awards totaling $400,000. This brings the total mesothelioma research funded…
The American Society for Clinical Oncology’s (ASCO) annual meeting concluded last week in Chicago, IL. As the largest oncology meeting in the world, ASCO is…
The pre-application period for the Peer Reviewed Cancer Research Program (PRCRP) submission is now open and accepting Letters of Intent (LOIs). To help researchers succeed…
On Thursday, March 23, at 9 AM EDT, the Mesothelioma Applied Research Foundation will be host a new episode of its Meet the Mesothelioma Experts…
UPDATE: On March 10, 2023, Merck announced through a press release that its Phase 3 study met its primary endpoint of overall survival which was…
The Mesothelioma Applied Research Foundation (Meso Foundation) is a non-profit organization that provides support, education, and advocacy for individuals and families affected by mesothelioma, a…
Mesothelioma in and of itself is a misunderstood diagnosis. As a cancer that affects roughly 3,000 Americans per year, it is often mistakenly thought of…
Last week, the Polaris Group announced positive results of its Phase 2/3 clinical trial evaluating the effectiveness of an arginine degrading enzyme agent called ADI-PEG 20.…
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
